{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:20:08Z","timestamp":1790083208210,"version":"4.0.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"DOI":"10.1007\/s42000-026-00763-6","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:15:35Z","timestamp":1774545335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current management of MASLD in type 2 diabetes"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5407-8548","authenticated-orcid":false,"given":"Valeria Michelle","family":"Fern\u00e1ndez-Garibay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-2814","authenticated-orcid":false,"given":"Vianney","family":"Sarabia-Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7451-3306","authenticated-orcid":false,"given":"Norberto C.","family":"Chavez-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"11","key":"763_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115640","volume":"25","author":"P Portincasa","year":"2024","unstructured":"Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, Baffy G, Di Ciaula A (2024) Metabolic dysfunction-associated steatotic liver disease: from pathogenesis to current therapeutic options. Int J Mol Sci 25(11):5640. https:\/\/doi.org\/10.3390\/ijms25115640","journal-title":"Int J Mol Sci"},{"key":"763_CR2","doi-asserted-by":"publisher","unstructured":"Ch\u00e1vez-Tapia NC, Vidal-Cevallos P (2024) Non-alcoholic fatty liver diseases or metabolic associated fatty liver disease\u2014Which is more comprehensive when associated with obesity? Obesity. Springer, Cham, 2nd edn. Switzerland, pp 111\u2013117. https:\/\/doi.org\/10.1007\/978-3-031-62491-9_8","DOI":"10.1007\/978-3-031-62491-9_8"},{"issue":"3","key":"763_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100261","volume":"3","author":"OT Ayonrinde","year":"2021","unstructured":"Ayonrinde OT (2021) Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD \u2013 reconciling the present with the past. JHEP Rep 3(3):100261. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100261","journal-title":"JHEP Rep"},{"issue":"1","key":"763_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Narro GEC, Chowdhury A, Cortez-Pinto H, Cryer DR et al (2024) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 29(1):101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133","journal-title":"Ann Hepatol"},{"issue":"2","key":"763_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/nu2020116","volume":"2","author":"JS Cohn","year":"2010","unstructured":"Cohn JS, Kamili A, Wat E, Chung RWS, Tandy S (2010) Dietary phospholipids and intestinal cholesterol absorption. Nutrients 2(2):116\u2013127. https:\/\/doi.org\/10.3390\/nu2020116","journal-title":"Nutrients"},{"issue":"6","key":"763_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060824","volume":"12","author":"F Nassir","year":"2022","unstructured":"Nassir F (2022) NAFLD: mechanisms, treatments, and biomarkers. Biomolecules 12(6):824. https:\/\/doi.org\/10.3390\/biom12060824","journal-title":"Biomolecules"},{"key":"763_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2024.142151","volume":"466","author":"B Kupikowska-Stobba","year":"2025","unstructured":"Kupikowska-Stobba B, Niu H, Klojdov\u00e1 I, Agreg\u00e1n R, Lorenzo JM, Kasprzak M (2025) Controlled lipid digestion in the development of functional and personalized foods for a tailored delivery of dietary fats. Food Chem 466:142151. https:\/\/doi.org\/10.1016\/j.foodchem.2024.142151","journal-title":"Food Chem"},{"issue":"8","key":"763_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrd1469","volume":"3","author":"Y Shi","year":"2004","unstructured":"Shi Y, Burn P (2004) Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 3(8):695\u2013710. https:\/\/doi.org\/10.1038\/nrd1469","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"763_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c170012","volume":"8","author":"M Alves-Bezerra","year":"2017","unstructured":"Alves-Bezerra M, Cohen DE (2017) Triglyceride metabolism in the liver. Compr Physiol 8(1):1\u201322. https:\/\/doi.org\/10.1002\/cphy.c170012","journal-title":"Compr Physiol"},{"issue":"3","key":"763_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S (2020) Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 130(3):1453\u20131460. https:\/\/doi.org\/10.1172\/JCI134165","journal-title":"J Clin Invest"},{"issue":"2","key":"763_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","volume":"91","author":"FWB Sanders","year":"2016","unstructured":"Sanders FWB, Griffin JL (2016) De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc 91(2):452\u2013468. https:\/\/doi.org\/10.1111\/brv.12178","journal-title":"Biol Rev Camb Philos Soc"},{"key":"763_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.119053","volume":"400","author":"S Iturbe-Rey","year":"2025","unstructured":"Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE, Lapitz A, Izquierdo-Sanchez L, Bujanda L, Perugorria MJ, Banales JM, Rodrigues PM (2025) Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis 400:119053. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119053","journal-title":"Atherosclerosis"},{"issue":"4","key":"763_CR13","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3748\/wjg.v22.i4.1664","volume":"22","author":"C Ress","year":"2016","unstructured":"Ress C, Kaser S (2016) Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol 22(4):1664. https:\/\/doi.org\/10.3748\/wjg.v22.i4.1664","journal-title":"World J Gastroenterol"},{"issue":"17","key":"763_CR14","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2174\/1389557523666230130093512","volume":"23","author":"J Rivera-Aguirre","year":"2023","unstructured":"Rivera-Aguirre J, L\u00f3pez-S\u00e1nchez GN, Ch\u00e1vez-Tapia NC, Uribe M, Nu\u00f1o-L\u00e1mbarri N (2023) Metabolic-associated fatty liver disease regulation through nutri epigenetic methylation. Mini Rev Med Chem 23(17):1680\u20131690. https:\/\/doi.org\/10.2174\/1389557523666230130093512","journal-title":"Mini Rev Med Chem"},{"key":"763_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155607","volume":"145","author":"WH Lee","year":"2023","unstructured":"Lee WH, Najjar SM, Kahn CR, Hinds TD (2023) Hepatic insulin receptor: new views on the mechanisms of liver disease. Metabolism 145:155607. https:\/\/doi.org\/10.1016\/j.metabol.2023.155607","journal-title":"Metabolism"},{"key":"763_CR16","doi-asserted-by":"publisher","unstructured":"Uehara K, Lee WD, Stefkovich M, Biswas D, Santoleri D, Garcia Whitlock A, Quinn W 3rd, Coopersmith T, Creasy KT, Rader DJ, Sakamoto K, Rabinowitz JD, Titchenell PM (2024) mTORC1 controls murine postprandial hepatic glycogen synthesis via Ppp1r3b. J Clin Invest 134(7). https:\/\/doi.org\/10.1172\/JCI173782","DOI":"10.1172\/JCI173782"},{"issue":"4","key":"763_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4161\/15384101.2014.991572","volume":"14","author":"M Morita","year":"2015","unstructured":"Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, Topisirovic I (2015) mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle 14(4):473\u2013480. https:\/\/doi.org\/10.4161\/15384101.2014.991572","journal-title":"Cell Cycle"},{"key":"763_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124003","author":"X Tan","year":"2023","unstructured":"Tan X, Huang X, Lu Z, Chen L, Hu J, Tian X, Qiu Z (2023) The essential effect of mtorc1-dependent lipophagy in non-alcoholic fatty liver disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1124003","journal-title":"Front Pharmacol"},{"issue":"3","key":"763_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","volume":"146","author":"JE Lambert","year":"2014","unstructured":"Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ (2014) Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146(3):726\u2013735. https:\/\/doi.org\/10.1053\/j.gastro.2013.11.049","journal-title":"Gastroenterology"},{"issue":"2","key":"763_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10555-023-10156-5","volume":"43","author":"F Su","year":"2024","unstructured":"Su F, Koeberle A (2024) Regulation and targeting of SREBP-1 in hepatocellular carcinoma. Cancer Metastasis Rev 43(2):673\u2013708. https:\/\/doi.org\/10.1007\/s10555-023-10156-5","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"763_CR21","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1136\/gutjnl-2024-333378","volume":"73","author":"M Van Hul","year":"2024","unstructured":"Van Hul M, Cani PD, Petitfils C, De Vos WM, Tilg H, El-Omar EM (2024) What defines a healthy gut microbiome? Gut 73(11):1893\u20131908. https:\/\/doi.org\/10.1136\/gutjnl-2024-333378","journal-title":"Gut"},{"issue":"1","key":"763_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","volume":"74","author":"S Ha","year":"2025","unstructured":"Ha S, Wong VWS, Zhang X, Yu J (2025) Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut 74(1):141\u2013152. https:\/\/doi.org\/10.1136\/gutjnl-2024-332398","journal-title":"Gut"},{"key":"763_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1568672","author":"H Yuan","year":"2025","unstructured":"Yuan H, Zhou J, Wu X, Wang S, Park S (2025) Enterotype-stratified gut microbial signatures in MASLD and cirrhosis based on integrated microbiome data. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2025.1568672","journal-title":"Front Microbiol"},{"issue":"1","key":"763_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12938\/bmfh.2020-046","volume":"40","author":"COM Jasirwan","year":"2021","unstructured":"Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I (2021) Correlation of gut Firmicutes\/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health 40(1):50\u201358. https:\/\/doi.org\/10.12938\/bmfh.2020-046","journal-title":"Biosci Microbiota Food Health"},{"issue":"9","key":"763_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10290","key":"763_CR26","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VWS, Rinella ME (2021) Non-alcoholic fatty liver disease. Lancet 397(10290):2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"issue":"6","key":"763_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101562","volume":"50","author":"J Pan","year":"2024","unstructured":"Pan J, Wu F, Chen M, He J, Gu Y, Pei L, Lai X, Zhang Z, Yang L (2024) Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999\u20132018. Diabetes Metab 50(6):101562. https:\/\/doi.org\/10.1016\/j.diabet.2024.101562","journal-title":"Diabetes Metab"},{"issue":"6","key":"763_CR28","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","volume":"22","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M (2024) Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020. Clin Gastroenterol Hepatol 22(6):1330\u20131332. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.003","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"763_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101898","volume":"30","author":"C Kan","year":"2025","unstructured":"Kan C, Zhang K, Wang Y, Zhang X, Liu C, Ma Y, Hou N, Huang N, Han F, Sun X (2025) Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990\u20132021 to 2045. Ann Hepatol 30(2):101898. https:\/\/doi.org\/10.1016\/j.aohep.2025.101898","journal-title":"Ann Hepatol"},{"issue":"3","key":"763_CR30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VWS Wong","year":"2023","unstructured":"Wong VWS, Ekstedt M, Wong GLH, Hagstr\u00f6m H (2023) Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 79(3):842\u2013852. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036","journal-title":"J Hepatol"},{"issue":"8","key":"763_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao YY, Zheng MH (2024) Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab 35(8):697\u2013707. https:\/\/doi.org\/10.1016\/j.tem.2024.02.007","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"763_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","volume":"13","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Paik JM, Henry L, Yang J, Fernandes G, Stepanova M, Nader F (2023) The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States. J Clin Exp Hepatol 13(3):454\u2013467. https:\/\/doi.org\/10.1016\/j.jceh.2022.12.005","journal-title":"J Clin Exp Hepatol"},{"issue":"8","key":"763_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40273-022-01140-y","volume":"40","author":"M Witkowski","year":"2022","unstructured":"Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S (2022) The economic burden of non-alcoholic steatohepatitis: a systematic review. Pharmacoeconomics 40(8):751\u2013776. https:\/\/doi.org\/10.1007\/s40273-022-01140-y","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"763_CR34","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, Tan DJH, Lim WH, Yong JN, Zeng R, Chee D, Nah B, Lesmana CRA, Bwa AH, Win KM, Faulkner C, Aboona MB, Lim MC, Syn N, Kulkarni AV, Suzuki H, Takahashi H, Tamaki N, Wijarnpreecha K, Huang DQ, Muthiah M, Ng CH, Loomba R (2023) Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 72(11):2138\u20132148. https:\/\/doi.org\/10.1136\/gutjnl-2023-330110","journal-title":"Gut"},{"key":"763_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhou XD, Shapiro MD, Lip GYH, Tilg H, Valenti L, Somers VK, Byrne CD, Targher G, Yang W, Viveiros O, Opio CK, Mantzoros CS, Ryan JD, Kok KYY, Jumaev NA, Perera N, Robertson AG, Abu-Abeid A, Misra A, Wong YJ, Ruiz-\u00dacar E, Ospanov O (2024) Global burden of metabolic diseases, 1990\u20132021. Metabolism 160:155999. https:\/\/doi.org\/10.1016\/j.metabol.2024.155999","journal-title":"Metabolism"},{"issue":"11","key":"763_CR36","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/03007995.2023.2262926","volume":"39","author":"J Fishman","year":"2023","unstructured":"Fishman J, Tapper EB, Dodge S, Miller K, Lewandowski D, Bogdanov A, Bonafede M (2023) The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data. Curr Med Res Opin 39(11):1425\u20131429. https:\/\/doi.org\/10.1080\/03007995.2023.2262926","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"763_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101778","volume":"30","author":"VM Fern\u00e1ndez-Garibay","year":"2025","unstructured":"Fern\u00e1ndez-Garibay VM, Chavez-Tapia NC (2025) The rationale for the aggressive progression of MASLD in patients with type 2 diabetes. Ann Hepatol 30(1):101778. https:\/\/doi.org\/10.1016\/j.aohep.2025.101778","journal-title":"Ann Hepatol"},{"issue":"4","key":"763_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"issue":"2","key":"763_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Wilson LA, Behling C, Kleiner DE, Kowdley KV, Dasarathy S, Amangurbanova M, Terrault NA, Diehl AM, Chalasani N, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, NASH Clinical Research Network, Loomba R (2023) Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology 165(2):463\u2013472. https:\/\/doi.org\/10.1053\/j.gastro.2023.04.025","journal-title":"Gastroenterology"},{"key":"763_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/JHC.S283840","volume":"9","author":"NC Chavez-Tapia","year":"2022","unstructured":"Chavez-Tapia NC, Mur\u00faa-Beltr\u00e1n Gall S, Ordo\u00f1ez-V\u00e1zquez AL, Nu\u00f1o-Lambarri N, Vidal-Cevallos P, Uribe M (2022) Understanding the role of metabolic syndrome as a risk factor for hepatocellular carcinoma. J Hepatocell Carcinoma 9:583\u2013593. https:\/\/doi.org\/10.2147\/JHC.S283840","journal-title":"J Hepatocell Carcinoma"},{"issue":"7","key":"763_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/apt.14937","volume":"48","author":"JG Stine","year":"2018","unstructured":"Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK (2018) Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 48(7):696\u2013703. https:\/\/doi.org\/10.1111\/apt.14937","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"763_CR42","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, Asch SM, El-Serag HB (2020) Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 71(3):808\u2013819. https:\/\/doi.org\/10.1002\/hep.31014","journal-title":"Hepatology"},{"issue":"2","key":"763_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020428","volume":"14","author":"E Michalopoulou","year":"2025","unstructured":"Michalopoulou E, Thymis J, Lampsas S, Pavlidis G, Katogiannis K, Vlachomitros D, Katsanaki E, Kostelli G, Pililis S, Pliouta L, Kountouri A, Papanikolaou IS, Lambadiari V, Ikonomidis I (2025) The triad of risk: linking MASLD, cardiovascular disease and type 2 diabetes; from pathophysiology to treatment. J Clin Med 14(2):428. https:\/\/doi.org\/10.3390\/jcm14020428","journal-title":"J Clin Med"},{"issue":"7","key":"763_CR44","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, Bardsley JK, Beverly EA, Corbin KD, ElSayed NA, Isaacs S, Kanwal F, Pekas EJ, Richardson CR, Roden M, Sanyal AJ, Shubrook JH, Younossi ZM, Bajaj M (2025) Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care 48(7):1057\u20131082. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care"},{"issue":"10","key":"763_CR45","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1111\/liv.16016","volume":"44","author":"DR Riley","year":"2024","unstructured":"Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ (2024) The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int 44(10):2538\u20132550. https:\/\/doi.org\/10.1111\/liv.16016","journal-title":"Liver Int"},{"key":"763_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156004","volume":"160","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros M, Henry L, Younossi ZM (2024) Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism 160:156004. https:\/\/doi.org\/10.1016\/j.metabol.2024.156004","journal-title":"Metabolism"},{"issue":"1","key":"763_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04017-x","volume":"23","author":"M Lee","year":"2025","unstructured":"Lee M, Hong S, Cho Y, Rhee H, Yu MH, Bae J, Lee YH, Lee BW, Kang ES, Cha BS (2025) Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial. BMC Med 23(1):266. https:\/\/doi.org\/10.1186\/s12916-025-04017-x","journal-title":"BMC Med"},{"issue":"1","key":"763_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89293-6","volume":"15","author":"GE Chung","year":"2025","unstructured":"Chung GE, Yu SJ, Yoo JJ, Cho Y, Lee KN, Shin DW, Kim YJ, Yoon JH, Han K, Cho EJ (2025) Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults. Sci Rep 15(1):5777. https:\/\/doi.org\/10.1038\/s41598-025-89293-6","journal-title":"Sci Rep"},{"issue":"7","key":"763_CR49","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD (2025) Metabolic dysfunction-associated steatotic liver disease. N Engl J Med 393(7):683\u2013698. https:\/\/doi.org\/10.1056\/NEJMra2412865","journal-title":"N Engl J Med"},{"issue":"7","key":"763_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26072959","volume":"26","author":"JE Mej\u00eda-Guzm\u00e1n","year":"2025","unstructured":"Mej\u00eda-Guzm\u00e1n JE, Belmont-Hern\u00e1ndez RA, Ch\u00e1vez-Tapia NC, Uribe M, Nu\u00f1o-L\u00e1mbarri N (2025) Metabolic-dysfunction-associated steatotic liver disease: molecular mechanisms, clinical implications, and emerging therapeutic strategies. Int J Mol Sci 26(7):2959. https:\/\/doi.org\/10.3390\/ijms26072959","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"763_CR51","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1111\/apt.17866","volume":"59","author":"WK Chan","year":"2024","unstructured":"Chan WK, Petta S, Noureddin M, Goh GBB, Wong VW (2024) Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity. Aliment Pharmacol Ther 59(Suppl 1):S23\u2013S40. https:\/\/doi.org\/10.1111\/apt.17866","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"763_CR52","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","volume":"65","author":"R Kwok","year":"2016","unstructured":"Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, Kong AP, Wong VW (2016) Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65(8):1359\u20131368. https:\/\/doi.org\/10.1136\/gutjnl-2015-309265","journal-title":"Gut"},{"issue":"5","key":"763_CR53","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/HEP.0000000000000860","volume":"82","author":"M Noureddin","year":"2025","unstructured":"Noureddin M (2025) Mash clinical trials and drugs pipeline: an impending tsunami. Hepatology 82(5):1325\u20131340. https:\/\/doi.org\/10.1097\/HEP.0000000000000860","journal-title":"Hepatology"},{"issue":"5","key":"763_CR54","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-024-03646-0","volume":"80","author":"M Kaur","year":"2024","unstructured":"Kaur M, Misra S (2024) A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol 80(5):669\u2013676. https:\/\/doi.org\/10.1007\/s00228-024-03646-0","journal-title":"Eur J Clin Pharmacol"},{"issue":"10401","key":"763_CR55","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529\u2013544. https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X","journal-title":"Lancet"},{"issue":"12","key":"763_CR56","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA, NN9931-4296 Investigators (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"2","key":"763_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 11(2):73. https:\/\/doi.org\/10.3390\/metabo11020073","journal-title":"Metabolites"},{"issue":"21","key":"763_CR58","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V, ESSENCE Study Group (2025) Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"763_CR59","unstructured":"FDA (2024) FDA approves treatment for serious liver disease known as MASH. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash. Accessed 1 Sept 2025"},{"issue":"10019","key":"763_CR60","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, H\u00fcbscher SG, Newsome PN (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"issue":"4","key":"763_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ, SYNERGY-NASH Investigators (2024) Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis. N Engl J Med 391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"6","key":"763_CR62","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndezLand\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1 (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10(6):393\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"763_CR63","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R, 1404-0043 Trial Investigators (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa2401755","journal-title":"N Engl J Med"},{"issue":"6","key":"763_CR64","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators (2023) Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N Engl J Med 389(6):514\u2013526. https:\/\/doi.org\/10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"issue":"7","key":"763_CR65","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 30(7):2037\u20132048. https:\/\/doi.org\/10.1038\/s41591-024-03018-2","journal-title":"Nat Med"},{"issue":"1","key":"763_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11010022","volume":"11","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G (2020) Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites 11(1):22. https:\/\/doi.org\/10.3390\/metabo11010022","journal-title":"Metabolites"},{"issue":"4","key":"763_CR67","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.dld.2023.09.023","volume":"56","author":"R Lombardi","year":"2024","unstructured":"Lombardi R, Mantovani A, Cespiati A, Francione P, Maffi G, Del Zanna E, Maffeis C, Colecchia A, Passigato N, Ferrarese A, Cusumanu CD, Villani R, Orsi E, Grancini V, Airaghi L, Bignamini D, Serviddio G, Targher G, Dongiovanni P, Fargion S, Fracanzani AL (2024) Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors. Dig Liver Dis 56(4):551\u2013558. https:\/\/doi.org\/10.1016\/j.dld.2023.09.023","journal-title":"Dig Liver Dis"},{"key":"763_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, Jia L, He J, Huang C, Wei X, Chen J, Chen X, Zhou J, Wu L, Zhang P, Zhu Y, Xia H, Wen G, Liu Y, Liu S, Zeng Y, Zhou L, Jia H, He H, Xue Y, Wu F, Zhang H (2025) Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735","journal-title":"BMJ"},{"issue":"6","key":"763_CR69","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2337\/dc25-0282","volume":"48","author":"A Mantovani","year":"2025","unstructured":"Mantovani A, Morandin R, Lando MG, Fiorio V, Pennisi G, Petta S, Stefan N, Tilg H, Byrne CD, Targher G (2025) Sodium-glucose cotransporter 2 inhibitor use and risk of liver-related events in patients with type 2 diabetes: a meta-analysis of observational cohort studies. Diabetes Care 48(6):1042\u20131052. https:\/\/doi.org\/10.2337\/dc25-0282","journal-title":"Diabetes Care"},{"issue":"1","key":"763_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","volume":"18","author":"S Francque","year":"2021","unstructured":"Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F (2021) Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 18(1):24\u201339. https:\/\/doi.org\/10.1038\/s41575-020-00366-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"763_CR71","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","volume":"74","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N (2021) Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology 74(4):1809\u20131824. https:\/\/doi.org\/10.1002\/hep.31843","journal-title":"Hepatology"},{"issue":"5","key":"763_CR72","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","volume":"78","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, Bedossa P, Cusi K, Ratziu V, Grouin JM, Moller DE, Fouqueray P (2023) Evaluation of PXL065 \u2013 deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1). J Hepatol 78(5):914\u2013925. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.004","journal-title":"J Hepatol"},{"issue":"5","key":"763_CR73","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"issue":"5","key":"763_CR74","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis. JAMA Intern Med 177(5):633\u2013640. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9607","journal-title":"JAMA Intern Med"},{"issue":"7","key":"763_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102174","volume":"47","author":"S Bandyopadhyay","year":"2023","unstructured":"Bandyopadhyay S, Samajdar SS, Das S (2023) Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 47(7):102174. https:\/\/doi.org\/10.1016\/j.clinre.2023.102174","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"12","key":"763_CR76","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","volume":"19","author":"MS Siddiqui","year":"2021","unstructured":"Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ (2021) A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 19(12):2670\u20132672. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.051","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"763_CR77","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.62185","volume":"8","author":"L Ji","year":"2025","unstructured":"Ji L, Ma J, Ma Y, Cheng Z, Gan S, Yuan G, Liu D, Li S, Liu Y, Xue X, Bai J, Wang K, Cai H, Li S, Liu K, Yu M, Liu L (2025) Berberine ursodeoxycholate for the treatment of type 2 diabetes. JAMA Netw Open 8(3):e2462185. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.62185","journal-title":"JAMA Netw Open"},{"issue":"1","key":"763_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25701-5","volume":"12","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, Goldkind L, Di Bisceglie AM (2021) A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun 12(1):5503. https:\/\/doi.org\/10.1038\/s41467-021-25701-5","journal-title":"Nat Commun"},{"issue":"1 Suppl 1","key":"763_CR79","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.2337\/dc25-S008","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care 48(1 Suppl 1):S167\u2013S180. https:\/\/doi.org\/10.2337\/dc25-S008","journal-title":"Diabetes Care"},{"issue":"20","key":"763_CR80","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","volume":"326","author":"A Aminian","year":"2021","unstructured":"Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, Albaugh VL, Shariff FU, Rodriguez NA, Jin J, Brethauer SA, Dasarathy S, Alkhouri N, Schauer PR, McCullough AJ, Nissen SE (2021) Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326(20):2031\u20132042. https:\/\/doi.org\/10.1001\/jama.2021.19569","journal-title":"JAMA"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00763-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00763-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00763-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:15:40Z","timestamp":1774545340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-026-00763-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":80,"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00763-6","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required since this article is a review that did not involve animals or human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This is a review article; therefore, informed consent was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}